Factor VIII biosimilar - Alphamab

Drug Profile

Factor VIII biosimilar - Alphamab

Alternative Names: KN 008

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator Alphamab
  • Developer Alphamab; Chia Tai Tianqing Pharmaceutical Group
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haemophilia

Most Recent Events

  • 22 Jul 2016 Phase-I clinical trials in Haemophilia in China (Parenteral) (Alphamab pipeline, July 2016)
  • 07 May 2015 Preclinical trials in Haemophilia in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top